RxDoctor Payments Data

Joseph Doe Iv, MD

Ophthalmology · Gaylord, MINPI 1407984909

Payments from drug & device makers

$2,323in general payments, 2019–2025

Across 55 payments — averaging $42.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$472
  • Bausch & Lomb Americas Inc.$390
  • Amgen$325
  • Johnson & Johnson Surgical Vision, Inc.$302
  • Alcon$293
  • Regeneron Healthcare Solutions, Inc.$231
  • plus $310 from 6 others

What the payments were for

  • Food & beverage$2,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,323 in reported general payments places this provider in the 65th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$357,586
Medicare patients
574
Services billed
4,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost160$93,291
RestasisCyclosporine20$32,392
RocklatanNetarsudil Mesylat/Latanoprost38$30,211
XiidraLifitegrast17$27,954
XdemvyLotilaner13$23,338
CombiganBrimonidine Tartrate/Timolol36$10,774
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat244$7,555
Latanoprost292$5,921
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$5,797
Travoprost23$5,526
Brimonidine Tartrate111$2,225
Timolol Maleate138$2,167
Tobramycin-DexamethasoneTobramycin/Dexamethasone47$2,129
Dorzolamide Hcl26$867
ErythromycinErythromycin Base58$726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$390$27,95417 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$31$23,33813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Gaylord

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →